When to Worry About a Rising Creatinine — and When Not To
📍 Alberta · ⏱️ 11 minute conversation · ✓ SGLT2i started, progression slowed
The Context
Dr. Michelle Cho had been watching Brian’s kidney function slowly decline for two years. Brian was 64, with type 2 diabetes and hypertension. His eGFR had gone from 58 to 52 to now 45. Creatinine was creeping up.
Brian was on metformin, ramipril, and amlodipine. His blood pressure was reasonable, his diabetes was moderately controlled (A1c 7.6%). He felt fine. But the trend was unmistakable.
Michelle had heard that SGLT2 inhibitors were now recommended for diabetic kidney disease — something about slowing progression. But she was nervous. Wouldn’t a drug that affected the kidneys make things worse? Brian’s eGFR was already 45. The prescribing information she’d read years ago said to avoid them in reduced kidney function.
She didn’t want to accelerate his decline toward dialysis.
The Question
“64-year-old man with type 2 diabetes, hypertension, and CKD — eGFR has declined from 58 to 45 over two years. On ramipril, metformin, amlodipine. A1c 7.6%. I’ve read that SGLT2 inhibitors are renoprotective, but I’m nervous about starting one with his eGFR already at 45. Is it safe? Will it actually help? And should I be adjusting any of his other medications?”
The Consult
Dr. Anita Iyer, a nephrologist, was reassuring — and encouraging.
“You should absolutely start an SGLT2 inhibitor. This is exactly the patient who benefits most. The trials — CREDENCE, DAPA-CKD, EMPA-KIDNEY — showed dramatic reductions in CKD progression, and the benefits were consistent even at eGFR as low as 20-25.”
She addressed Michelle’s concern directly: “Yes, you’ll see a small dip in eGFR when you start — usually 3-5 points. That’s expected and not harmful. It’s a hemodynamic effect, not damage. It stabilizes and then the long-term trajectory improves. Don’t stop it because of that initial dip.”
For Brian specifically: start empagliflozin 10mg or dapagliflozin 10mg daily. Continue the ramipril — ACE inhibitors and SGLT2 inhibitors are complementary, not redundant. Make sure he’s on a statin if not already (cardiovascular risk). Check creatinine and potassium in 2-4 weeks, but expect that small dip.
“The old prescribing cutoffs are outdated. We now start SGLT2 inhibitors down to eGFR 20, and continue them even lower. You’re not going to hurt him — you’re going to protect his kidneys.”
The Outcome
Michelle started Brian on empagliflozin 10mg. She warned him about the expected small creatinine bump and scheduled labs for three weeks.
| Conversation duration | At 12 months | Outcome |
| 11 min | eGFR stable at 43 | Progression slowed |
At three weeks: eGFR had dipped to 42. Michelle resisted the urge to stop the medication.
At six months: eGFR 43. Stable. A1c had dropped slightly to 7.3% as a bonus.
At twelve months: still 43. For the first time in three years, Brian’s kidney function hadn’t declined.
“So we stopped the slide?” Brian asked.
“We stopped the slide.”
What the Physician Learned
“I was afraid of SGLT2 inhibitors in CKD because of outdated information. I thought they were contraindicated when kidney function was reduced. The nephrologist explained that the opposite is true — these drugs are most beneficial in exactly these patients. The initial eGFR dip scared me at first, but I trusted the guidance, and Brian’s kidneys have been stable ever since. I’ve now started SGLT2 inhibitors in a dozen CKD patients. It’s become standard in my practice.”
— Dr. Michelle Cho, Family Physician, Alberta
Have a patient with declining kidney function?
Get guidance on renoprotective therapies and when to start them.